TipRanks on MSN

Bristol-Myers Squibb’s Luspatercept Study: A Potential Game-Changer for Alpha-Thalassemia

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

90% of US Adults Affected by Condition Most People Have Never Heard Of

A recent survey from the American Heart Association asked 4,007 adults a series of questions about CKM health and found that ...

Why your late teens and early 20s are crucial times for lifelong heart health

Meanwhile, fewer than half of adults ages 18-34 recognize high cholesterol, obesity, high blood pressure and lack of physical ...
The Nation UAE on MSN

Meeting mulls improving thalassemia prevention, bone marrow transplants

A meeting was held on Tuesday under the chair­manship of Federal Health Minister Mustafa Kamal to dis­cuss strategies for preventing thalassemia and making bone marrow transplants more accessible to ...

Study unveils mechanisms driving axonal accumulation of TDP-43 and associated nerve damage in ALS

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive muscle wasting and limb ...
Neurology Advisor

Plasma Phosphorylated Tau 217 Effectively Identifies Preclinical Alzheimer Disease

Plasma p-tau217 demonstrates strong accuracy in identifying Aβ pathology among cognitively unimpaired individuals.
Daily Mirror

India’s rising developmental & humanitarian leadership in South Asia

India has emerged as South Asia’s humanitarian and developmental leader, extending over USD 30 billion during the last 10 years in aid through financial, in-kind, and capacity-building support. Guided ...

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals Incorporated: Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK at the North American Cystic Fibrosis Conference

Data presented on outcomes following treatment with CFTR modulators add to growing body of evidence that reduced level of sweat chloride is associated with improved clinical outcomes, particularly ...